Zacks Investment Research Lowers Stoke Therapeutics (NASDAQ:STOK) to Sell

Zacks Investment Research lowered shares of Stoke Therapeutics (NASDAQ:STOK) from a hold rating to a sell rating in a research note published on Tuesday morning, Zacks.com reports.

According to Zacks, “Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company’s product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford, Massachusetts. “

A number of other research analysts have also weighed in on the company. Cantor Fitzgerald reaffirmed an overweight rating on shares of Stoke Therapeutics in a research report on Tuesday, November 9th. JPMorgan Chase & Co. upgraded Stoke Therapeutics from a neutral rating to an overweight rating and set a $41.00 price target for the company in a report on Monday, November 22nd. Bank of America assumed coverage on shares of Stoke Therapeutics in a research note on Friday, December 3rd. They issued a buy rating and a $43.00 price target on the stock. Finally, HC Wainwright restated a buy rating and set a $70.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, September 22nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Stoke Therapeutics has a consensus rating of Buy and a consensus target price of $57.50.

NASDAQ:STOK opened at $19.58 on Tuesday. The firm’s 50-day moving average price is $23.10 and its 200-day moving average price is $25.62. The company has a market capitalization of $720.37 million, a PE ratio of -9.37 and a beta of 0.16. Stoke Therapeutics has a 1-year low of $17.76 and a 1-year high of $71.58.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Monday, November 8th. The company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.04). As a group, analysts expect that Stoke Therapeutics will post -2.31 EPS for the current fiscal year.

In other Stoke Therapeutics news, COO Huw M. Nash sold 5,700 shares of Stoke Therapeutics stock in a transaction that occurred on Wednesday, December 1st. The shares were sold at an average price of $24.44, for a total value of $139,308.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Huw M. Nash sold 3,800 shares of the business’s stock in a transaction on Monday, January 3rd. The shares were sold at an average price of $23.07, for a total transaction of $87,666.00. The disclosure for this sale can be found here. Insiders sold a total of 15,200 shares of company stock valued at $363,926 over the last quarter. 51.80% of the stock is owned by corporate insiders.

A number of large investors have recently made changes to their positions in the business. Ameritas Investment Partners Inc. increased its position in shares of Stoke Therapeutics by 38.7% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,497 shares of the company’s stock valued at $50,000 after purchasing an additional 418 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of Stoke Therapeutics by 35.7% in the second quarter. Legal & General Group Plc now owns 2,720 shares of the company’s stock worth $92,000 after buying an additional 715 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Stoke Therapeutics during the third quarter valued at approximately $130,000. Amundi purchased a new stake in Stoke Therapeutics during the second quarter valued at approximately $178,000. Finally, Metropolitan Life Insurance Co NY increased its holdings in Stoke Therapeutics by 140,250.0% during the second quarter. Metropolitan Life Insurance Co NY now owns 5,614 shares of the company’s stock valued at $189,000 after buying an additional 5,610 shares during the last quarter. 52.46% of the stock is currently owned by institutional investors and hedge funds.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Featured Story: What is the Current Ratio?

Get a free copy of the Zacks research report on Stoke Therapeutics (STOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Stoke Therapeutics (NASDAQ:STOK)

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.